A Kyoto University research team has developed a pain-reliever that is comparable to morphine but does not have serious side effects.<\/p>\n
Morphine, often administered to cancer patients, has serious adverse effects such as breathing issues and addiction.<\/p>\n
According to the team, the newly developed drug, Adriana, is a groundbreaking painkiller, which works on a completely different mechanism to morphine and other existing synthetic opioids. The drug has the potential to revolutionize pain control in the medical field, the team said.<\/p>\n
The team also expects that the drug will help resolve the so-called opioid epidemic, in which a large number of deaths occur mainly due to overdoses of opioids.<\/p>\n
Its findings were published in the online edition of the U.S. journal Proceedings of the National Academy of Sciences.<\/p>\n
When a person encounters a life-threatening situation, norepinephrine, an organic chemical secreted from the brain, suppresses pain.<\/p>\n
For its study, the team focused on the human body regulating oversecretion of norepinephrine. By introducing a new research technology, the team succeeded in developing a drug blocking such a control function for the first time in the world.<\/p>\n
In a clinical trial conducted at the Kyoto University Hospital between January 2023 and December 2024, the team confirmed the new drug’s efficiency to a certain extent for patients including 20 who underwent lung cancer surgery.<\/p>\n
The team plans to conduct a clinical trial in the United States for 400 postsurgery patients in 2026, aiming to put Adriana into practical use in 2028.<\/p>\n
“We hope that the new drug will help cancer patients who previously had no choice but to use opioids live their lives without pain as well as a need to worry about addiction or serious side effects,” Masatoshi Hagiwara, a professor at the university, said.<\/p>\n","protected":false},"excerpt":{"rendered":"A Kyoto University research team has developed a pain-reliever that is comparable to morphine but does not have…\n","protected":false},"author":2,"featured_media":45351,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[847,59,102,25708,3100,13214,56,54,55],"class_list":["post-45350","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-cancer","tag-gb","tag-health","tag-kyoto-university","tag-medicine","tag-pharmaceuticals","tag-uk","tag-united-kingdom","tag-unitedkingdom"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/45350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=45350"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/45350\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/45351"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=45350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=45350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=45350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}